title: Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin.
abstract: In order to investigate the mechanism of topoisomerase I inhibition by camptothecin, we studied the induction of DNA cleavage by purified mammalian DNA topoisomerase I in a series of oligonucleotides and analyzed the DNA sequence locations of preferred cleavage sites in the SV40 genome. The oligonucleotides were derived from the sequence of the major camptothecin-induced cleavage site in SV40 DNA (Jaxel, C., Kohn, K. W., and Pommier, Y. (1988) Nucleic Acids Res. 16, 11157 to 11170) with the cleaved bond in their center. DNA length was critical since cleavage was detectable only in 30 and 20 base pair-(bp) oligonucleotides, but not in a 12-bp oligonucleotide. Cleavage was at the same position in the oligonucleotides as in SV40 DNA. Its intensity was greater in the 30- than in the 20-bp oligonucleotide, indicating that sequences more than 10 bp away from the cleavage site may influence intensity. Camptothecin-induced DNA cleavage required duplex DNA since none of the single-stranded oligonucleotides were cleaved. Analysis of base preferences around topoisomerase I cleavage sites in SV40 DNA indicated that camptothecin stabilized topoisomerase I preferentially at sites having a G immediately 3' to the cleaved bond. Experiments with 30-bp oligonucleotides showed that camptothecin produced most intense cleavage in a complementary duplex having a G immediately 3' to the cleavage site. Weaker cleavage was observed in a complementary duplex in which the 3'G was replaced with a T. The identity of the 3' base, however, did not affect topoisomerase I-induced DNA cleavage in the absence of drug. These results indicate that camptothecin traps preferentially a subset of the enzyme cleavage sites, those having a G immediately 3' to the cleaved bond. This strong preference suggests that camptothecin binds reversibly to the DNA at topoisomerase I cleavage sites, in analogy to a model previously proposed for inhibitors of topoisomerase II (Capranico, G., Kohn, K.W., and Pommier, Y. (1990) Nucleic Acids Res. 18, 6611-6619).
authors.affiliation: Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: C
authors.initials: C
authors.lastname: Jaxel
authors.forename: G
authors.initials: G
authors.lastname: Capranico
authors.forename: D
authors.initials: D
authors.lastname: Kerrigan
authors.forename: K W
authors.initials: KW
authors.lastname: Kohn
authors.forename: Y
authors.initials: Y
authors.lastname: Pommier
mesh_terms: D000818:Animals; D001483:Base Sequence; D002166:Camptothecin / Q000494:pharmacology*; D004264:DNA Topoisomerases, Type I / Q000235:genetics* / Q000378:metabolism; D004273:DNA, Neoplasm / Q000235:genetics* / Q000378:metabolism; D006868:Hydrolysis; D007939:Leukemia L1210 / Q000201:enzymology; D051379:Mice; D008969:Molecular Sequence Data; D013379:Substrate Specificity
chemical_list: D004273:DNA, Neoplasm; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin